6 results
To evaluate the safety and efficacy of 2 dose levels of BOTOX® (200 U or 300 U) compared to placebo injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have not been…
To describe the course of symptoms of BPS/IC after intravesical injection of Botox®.
The objective is to find out whether injection of Botulinum toxin A into the wall of the bladder has, besides effects on bladder capacity and urgency symptoms, any influence on the contractility of the detrusor muscle.
Primary objective is the delta change in whole body insulin sensitivity upon Na-PB vs. placebo treatment. Secondary objectives are muscle mitochondrial oxidative capacity, muscle and liver fat content and energy metabolism.
Secondary objectives:The secondary objectives include demonstration of clinical efficacy of SCIT with BM41 alone, with BM41 plus VD3 and with VD3 alone, all three compared to placebo. Efficacy will be analysed for the upper airways by titrated nasal…
To evaluate the safety and efficacy of BOTOX for the treatment of urinary incontinencedue to overactive bladder (OAB) in patients 12 to 17 years of age who have not been adequately managed with anticholinergic therapy. To evaluate the safety and…